Over the past four years, we’ve transformed fundamental research into real-world impact developing lipid systems that protect active pharmaceutical ingredients from degradation, enhance bioavailability, and expand formulation possibilities.

As we celebrate our 4th anniversary, we take pride in the progress made and the partnerships that have fueled our growth. Together with our collaborators, we are committed to advancing the next generation of therapeutics bridging science and application to create safer, more effective treatments for patients worldwide.

We were honored to welcome Federal Minister Dr. Wolfgang Hattmannsdorfer, Bundesvorsitzende der Jungen Wirtschaft Bettina Dorfer-Pauschenwein, and their teams from the Federal Ministry for Economic Affairs and Energy and the Austrian Federal Economic Chamber to NovoArc GmbH. We opened our doors to showcase our proprietary archaeal lipid technology, state-of-the-art laboratories, and the team behind our innovation.

Together, we explored how Austria can evolve from a nation of strong research excellence into a global market leader by fostering translational capabilities, scaling manufacturing capacity, and encouraging cross-border collaborations. Strengthening commercialization pathways and venture support for emerging biotech companies was identified as key to bridging the gap between the lab and the global marketplace.

During the visit, we also presented our product portfolio demonstrating how our lipid systems enhance stability, bioavailability, and formulation flexibility for next-generation therapeutics. The future of biotech innovation depends on people. We reflected on how Austria can nurture a new generation of talent with the interdisciplinary skills essential for bioprocessing, data-driven biotechnology, and analytical platforms. As a company committed to bridging science and application, we take pride in contributing to Austria’s growing biotech ecosystem transforming fundamental research into impact, one breakthrough at a time.

One of the greatest challenges in drug development is ensuring that active pharmaceutical ingredients (APIs) reach their target in the body at the right place, in the right dosage, and at the right time.

While oral administration is the most convenient and most preferred route for patients, many promising APIs face critical limitations: degradation in the harsh environment of the digestive tract or insufficient absorption across the intestinal barrier. These issues lead to poor bioavailability, preventing their full therapeutic potential from being realized.

Through Lipidosa, NovoArc aims to unlock new possibilities for stable and efficient oral drug delivery by leveraging our unique tetraether lipid technology.

This project focuses on the development of a rapid antigen identification platform, with the aim of accelerating next-generation mRNA vaccine development and enabling faster responses to emerging infectious diseases, an urgent need that remains highly relevant in the post-COVID era.
As part of this initiative, NovoArc contributes its lipid-based formulation technology to advance innovative solutions for efficient mRNA vaccine delivery.

Univ. Prof. Oliver Spadiut presented how NovoArc’s next-generation lipid platform is redefining drug delivery by enabling the oral administration of biologics, small molecules, and nucleic acids.

Key insight from the session: Stability and efficient delivery remain central challenges in therapeutic development. NovoArc’s lipid technology offers a breakthrough solution to address these barriers and unlock new possibilities in advanced therapies.

We had the pleasure of speaking at the 8th International Symposium on Phospholipids in Pharmaceutical Research last week, where there was even a dedicated session on Tetraether lipids an exciting development for a field that’s gaining momentum.

The event was full of insightful presentations and engaging discussions, and it was a privilege to be part of it.

A big thank you to everyone who made the event a success! Looking forward to more exciting developments in the future.

During his visit, he showed great interest in our technology and was impressed by our innovative approach.
The Minister toured our company premises, and we engaged in an exciting discussion about the future of biotechnology in Austria. His positive feedback reinforces our mission to develop groundbreaking solutions.

Thank you, Minister, for your support and the inspiring conversations! We look forward to advancing our innovations and bringing Austria to the forefront of the biotech industry.